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Abstract
Purpose Clinical studies have shown that low-level laser
therapy (LLLT) can improve local tissue healing of
bisphosphonate-induced osteonecrosis of the jaw. However,
the effects of laser irradiation on bisphosphonate-treated oste-
oblasts have not been completely elucidated.
Methods Human osteoblasts were cultured in plain culture
medium (DMEM). After 48 h, plain DMEM was replaced
by DMEM with no fetal bovine serum, for a 24-h incubation
followed by addition of zoledronic acid (5 μM) for additional
48 h. Cells were subjected to LLLT (InGaAsP; 780±3 nm;
0.025 W) at 0.5, 1.5, 3, 5, and 7 J/cm2, three times every 24 h.
Cell viability, total protein production, alkaline phosphatase
activity (ALP), mineral nodule formation, gene expression of
collagen type I and ALP, and cell morphology were
evaluated.
Results LLLT at 0.5 J/cm2 increased cell viability of cultured
osteoblasts. ALP activity and gene expression, in addition to
mineral nodule formation and Col-I gene expression, were not
increased by LLLT. LLLT applied to ZA-treated cells in-
creased Col-I expression at 0.5, 1.5, and 3 J/cm2 but did not
improve any other cell activity assessed.
Conclusion LLLT showed limited effects on bisphosphonate-
treated osteoblasts.
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Introduction
Bisphosphonate-related osteonecrosis has been considered to
have an adverse effect on bisphosphonate treatment [1, 2].
This condition is described in approximately 1 % of patients,
but its incidence is directly related to the type of bisphospho-
nate, treatment period, and administration of the drug [1, 2]. In
addition, oral health conditions, such as the presence of in-
flammatory conditions and trauma, have also been related to
the development and maintenance of osteonecrosis [1–3].
Elucidation of the etiopathogenesis and treatment strategies
for osteonecrosis has become critical, since its incidence has
increased, associated with the fact that, in most cases,
osteonecrosis can be very painful and frequently affects pa-
tients’ quality of life [1–5].
Increased incidence of bisphosphonate-related osteonecrosis
of the jaw has led to studies of the etiopathogenesis protocols
[1, 2] and treatment [3] for this adverse effect of bisphosphonate
treatment. It is known that the occurrence of osteonecrosis is
associated, at least in part, with the type of bisphosphonate
used, its administration, frequency, and duration of treatment.
Additionally, this pathological condition may be associated
with local factors, such as the presence of biofilm, inflamma-
tory process, and direct cytotoxicity of bisphosphonates to oral
mucosa cells [2, 4, 5].
Previous studies have shown that bisphosphonates have
toxic effects on osteoblast, fibroblast, epithelial, and endothe-
lial cells [5–7]. In addition, many researchers have
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demonstrated that bisphosphonates can delay oral healing
process as well as decrease bone formation and neovascular-
ization [8, 9].
Standard strategies for the treatment of osteonecrosis of the
jaw include local and systemic antibiotic administration and
surgical intervention [1, 3]. Recent clinical reports have dem-
onstrated that treatment of osteonecrotic lesions with low-
level laser therapy (LLLT) in association with antimicrobial
or surgical treatment improves tissue healing and reduces
localized pain [10–13].
Positive effects of LLLT on different cell types have been
demonstrated in several in vitro and in vivo studies [14, 15].
However, only scarce data have been provided concerning
the effects of laser irradiation on oral tissues, especially on
bone cells exposed in osteonecrotic jaw lesions.
Elucidation of the effects of LLLT on zoledronic
acid-treated cells may validate or improve the safe use
of this non-invasive therapy for osteonecrosis of the jaw
for the treatment of patients receiving bisphosphonates
and presenting osteonecrosis lesions. Therefore, the aim
of this study was to evaluate the effects of LLLT on
specific parameters of cultured osteoblasts, whether pre-
viously exposed to a specific type of bisphosphonate–
zoledronic acid.
Materials and methods
Cell culture
An immortalized human osteoblastic cell line was selected for
study (Saos-2–HTB-85). Cells were seeded in wells of 24-
well plates in complete culture medium (DMEM-Gibco,
Grand Island, NY, USA) supplemented with 10% fetal bovine
serum (FBS-Gibco) and maintained in a 5 % CO2atm at
37 °C.
Zoledronic acid treatment
After 48-h incubation, the plain culture medium in contact
with cells was replaced by serum-free DMEM. Following an
additional 24-h incubation, ZA at 5 μM was added to the
serum-free DMEM, which was maintained in contact with
osteoblasts for 48 h.
ZA was used in this study because it is a highly
potent bisphosphonate that has been frequently associat-
ed with osteonecrosis of the jaws. The ZA concentration
used was based on a previous study in which the
authors showed that 5 μM is the highest concentration
of ZA found in the saliva and bone tissue of patients
under ZA treatment [6].
LLLT
LLLTwas performed with a laser diode prototype widely used
in previous studies (LASERTable, InGaAsP; 780±3 nm;
0.025 W), since it provides complete, uniform, and standard-
ized irradiation of the bottoms of the wells to which the seeded
cells are attached [16–18]. Before each experiment, delivery
energy was measured at the bottoms of the 24-well plates, to
confirm LLLT parameters. The cells were irradiated every
24 h for specific times according to the energy doses of
0.5 J/cm2 (40 s), 1.5 J/cm2 (120 s), 3 J/cm2 (240 s), 5 J/cm2
(400 s), and 7 J/cm2 (560 s). Cells were irradiated at a
standardized distance of 2 cm, and the area of irradiation
was also standardized at 2 cm2.
The LLLT parameters used in this in vitro study were
selected according to previous investigations in which the
authors irradiated cultured osteoblasts, demonstrating in-
creased cell viability and function [19–21].
Cell viability—MTT assay
Twenty-four hours after the last irradiation, the osteoblasts’
viability was assessed by MTT assay (n=8), which is a well-
described and standardized test that provides cell mitochon-
drial activity. The protocol was performed as previously de-
scribed [16].
Total protein production
The total protein production by osteoblasts (n=8), whether
exposed to ZA and whether subjected to different levels of
LLLT, was analyzed by an end-point colorimetric test as
described previously [16].
Alkaline phosphatase activity (ALP)
ALP activity is considered a phenotypicmarker of osteoblasts,
and alterations to this activity can affect osteoblastic mineral-
ization functions. This assay is based on thymolphthaline
hydrolysis by ALP and was performed as previously de-
scribed (n=8) [22].
Mineralization nodule formation—alizarin red stain
Mineralization nodule formation was assessed by alizarin red
stain, which also demonstrates the phenotypic capacity of
osteoblasts to form a mineralized matrix [18].
For mineral nodule formation, cells were maintained in an
osteogenic culture medium composed of DMEM (Gibco)
containing 10 % FBS (Gibco), ß-glycerophosphate (Sigma-
Aldrich, St. Louis, MO, USA), and ascorbic acid (Sigma-
Aldrich) (n=8) [22].
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Briefly, after ZA treatment and LLLT application, cells
were fixed in 70 % cold ethanol for 1 h. Immediately after
the samples were rinsedwith deionized water, mineral nodules
were detected by alizarin red (40 nm; pH 4.2) incubation
under shaking for 20 min at room temperature. For quantita-
tive analysis, mineral nodules were dissolved in 10 %
cetylpyridinium chloride (Sigma-Aldrich) for 15 min under
shaking. Finally, mineral nodule formation was assessed by
absorbance at 692 nm (Thermo Plate, Nanshan District,
Shenzhen, China).
Gene expression—real-time PCR
Real-time PCR was used to evaluate the gene expression of
Col-I and ALP as previously described (n=4) [23]. These
genes participate in matrix synthesis and mineralization.
Briefly, messenger RNA (mRNA) isolation was obtained
by the Trizol (Invitrogen, Carlsbad, CA, USA) method,
followed by complementary DNA (cDNA) synthesis, with a
high-capacity cDNA kit (Invitrogen).
For PCR analysis, specific primers and probe sets were
designed. PCR reactions were prepared with standardized
SYBR® Green reagents (Applied Biosystems, Foster City,
CA, USA) for ALP analysis or Taqman reagents (Applied
Biosystems) for Col-I and RPL13 analysis. These reactions
were performed in the Step One Plus Real Time System
(Applied Biosystems). Data were analyzed by Step One Plus
Software (Applied Biosystems) with relative quantitation of
each mRNA, considering constitutive gene (RPL13).
Scanning electronic microscopy (SEM)
Osteoblast morphology, whether exposed to ZA and whether
subjected to LLLT, was evaluated by SEM. Cells were seeded
on 13-mm sterile glass discs previously placed on the bottoms
of wells of 24-well plates. After the osteoblasts were treated as
described in Table 1, the cells were fixed with 2.5 % glutar-
aldehyde (Sigma-Aldrich), post-fixed with 1 % osmium te-
troxide, and dehydrated in increasing ethanol concentrations
(30, 50, 95, and 100 %). Finally, the cells were subjected to
chemical drying with 1,1,1,3,3,3 hexamethyldisilazane
(HMDS, Sigma-Aldrich).
The glass discs with cells on them were mounted in metal-
lic stubs and stored in a desiccator for 7 days. The samples
were then gold-sputtered, and cell morphology was assessed
by SEM (Inspect Scanning Electron Microscope-S50, FEI,
Hillsboro, OR, USA).
Statistical analysis
Cell viability, total protein production, mineral nodule forma-
tion, and qPCR data were analyzed by Kruskal–Wallis tests
Table 1 Viability of osteoblasts, whether exposed to ZA and then subjected to LLLT at different energy doses
ZA Energy doses (J/cm2)
0 0.5 1.5 3 5 7
+ 34 (31–60)
B, a
39 (33–52)
B, a
36 (34–51)
B, a
36 (34–55)
B, a
31 (29–57)
B, a
33 (30–58)
B, a
− 101 (98–104)
A, bc
113 (107–115)
A, a
107 (106–113)
A, ab
106 (102–109)
A, bc
102 (95–107)
A, bc
104 (101–106)
A, bc
Values indicate median (25th to 75th percentiles), n=8
A, a Same upper-case letters in columns and lower-case letters in rows indicate no statistically significant difference (Mann–Whitney, p>0.05)
Table 2 Total protein production by osteoblasts irradiated with LLLT and treated with ZA
ZA Energy doses (J/cm2)
0 0.5 1.5 3 5 7
+ 61.34
(58.83-66.53)
B, a
65.56
(57.48–75.02)
B, a
54.58
(49.26–64.40)
B, ab
54.53
(48.22–60.30)
B, ab
48.87
(41.33–53.47)
B, ab
39.86
(31.99–49.02)
B, a
− 100.22
(98.19–101.27)
A, a
109.02
(103.81–110.07)
A, a
103.81
(99.53–104.37)
A, a
100.23
(97.63–103.41)
A, a
98.04
(89.97–101.88)
A, a
101.06
(84.81–105.56)
A, a
Values indicate median (25th to 75th percentiles), n=8
A, a Same upper-case letters in columns and lower-case letters in rows indicate no statistically significant difference (Mann–Whitney, p>0.05)
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complemented by Mann–Whitney tests, for groups. Statistical
significance was set at 5 %. All experimental protocols were
performed on three different occasions.
Results
In general, ZA caused an intense decrease in osteoblasts and
viability, and, on the other hand, LLLT at 0.5 J/cm2 increased
viability of these cultured cells. However, osteoblasts exposed
to ZA and subjected to laser irradiation presented no improve-
ment in viability (Table 1).
In terms of total protein production, no difference was
observed among all groups in which the cells were subjected
to LLLT, whether or not they were exposed to ZA (Table 2).
As determined for cell viability, osteoblasts treated only with
ZA showed a significant decrease in total protein production.
The ALP activity of osteoblasts, whether or not they were
treated with ZA, was not influenced by laser irradiation. The
LLLT at energy doses of 3 and 7 J/cm2 reduced ALP activity
only slightly. In contrast, the same laser energy doses signif-
icantly decreased this enzyme activity in osteoblasts previous-
ly exposed to ZA (Table 3).
None of the laser energy doses evaluated in this study
biostimulated mineral nodule formation by osteoblasts. When
the cells were previously treated with ZA, the capacity for
mineral nodule formation by cultured osteoblasts was signif-
icantly reduced (Table 4).
Gene expression of Col-I by osteoblasts subjected to
all laser energy doses tested was similar to that of
osteoblasts in the control group. However, for ZA-
treated cells subjected to LLLT at 0.5, 1.5, and 3 J/
cm2, a significant increase in Col-l expression was ob-
served (Table 5).
Increased ALP gene expression was observed only when
the osteoblasts were subjected to LLLTat 1.5 J/cm2. However,
laser irradiation did not modulate the ALP gene expression in
those cells previously treated with ZA (Table 6). Osteoblasts
subjected only to ZA treatment showed significant decreases
in Col-I and ALP expression.
The SEM evaluation of osteoblasts treated with ZA
showed the occurrence of intense morphological cell
alterations characterized by cytoplasm shrinkage as well
as disaggregation and disruption of this cellular struc-
ture. Similar osteoblast alterations were also observed
when the ZA-treated cells were subjected to LLLT
(Figs. 1 and 2).
Increased numbers of cells attached to the glass substrate
were seen when the osteoblasts were solely laser-irradiated at
an energy dose of 5 J/cm2. Cells subjected to all LLLT tested
in this study exhibited normal morphology, as observed in the
control group (Figs. 1 and 2).
Table 3 Alkaline phosphatase activity by osteoblasts after ZA treatment followed by LLLT
ZA Energy doses (J/cm2)
0 0.5 1.5 3 5 7
+ 35.56
(34.64–37.52)
B, a
33.96
(30.21–36.13)
B, a
26.43
(21.82–31.45)
B, ab
20.57
(17.10–22.47)
B, b
27.95
(21.71–30.02)
B, ab
23.13
(17.74–24.65)
B, b
− 100.15
(93.96–106.53)
A, ab
103.56
(101.88–106.70)
A, a
99.87
(90.13–106.19)
A, ab
89.57
(85.00–92.66)
A, b
98.06
(83.46–101.34)
A, ab
95.71
(91.88–103.99)
A, ab
Values indicate median (25th to 75th percentiles), n=8
A, a Same upper-case letters in columns and lower-case letters in rows indicate no statistically significant difference (Mann–Whitney, p>0.05)
Table 4 Mineral nodule formation by osteoblasts after ZA and LLLT treatment
ZA Energy doses (J/cm2)
0 0.5 1.5 3 5 7
+ 6.26
(5.82–6.82)
B, a
8.34
(7.99–8.81)
B, a
6.35
(5.83–6.93)
B, a
5.88
(5.29–6.58)
B, a
7.88
(7.70–8.64)
B, a
6.76
(6.40–7.17)
B, a
− 96.41
(95.59–101.29) A, ab
99.98
(97.18–102.34) A, a
96.69
(95.24–96.94) A, ab
88.74
(85.48–93.98) A, b
88.26
(84.77–93.06) A, b
97.07
(96.47–97.35) A, ab
Values indicate median (25th to 75th percentiles), n=8
A, a Same upper-case letters in columns and lower-case letters in rows indicate no statistically significant difference (Mann–Whitney, p>0.05)
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Discussion
Several studies have evaluated the effects of ZA on osteo-
blasts, since this drug has been related to the etiopathogenesis
of osteonecrosis as well as to delayed bone healing and
remodeling in patients under ZA treatment [22]. In the present
study, a highly cytotoxic effect was observed in osteoblasts
treated with ZA, characterized by decreased viability, total
protein production, mineral nodule formation, ALP activity
and morphology, and gene expression of Col-I and ALP.
Several studies have introduced LLLT as an adjuvant ther-
apy for bisphosphonate-induced osteonecrosis associated with
antimicrobial or surgical treatment and have shown that this
therapy can accelerate healing and lesion remission [10–13].
Low-power laser-irradiated osteoblasts enhance proliferation
and protein synthesis, mainly those related to matrix forma-
tion and maturation, such as Col-I [20, 25, 26].
It was shown in the present study that specific parameters
of LLLT can biostimulate osteoblasts in culture, increasing
their viability. However, no effects of laser irradiation were
observed on mineral nodule formation, ALP activity, and
expression of genes related to matrix production and mineral-
ization. The absence of positive effects of LLLTon ZA-treated
cells may be related to the selected parameters of irradiation,
since previous studies have demonstrated that different wave-
lengths, power outputs, or energy doses can promote diverse
cellular responses [24]. As reported by other authors, higher
energy doses can increase the metabolism of cultured osteo-
blasts [26, 27].
The data obtained in the present study may also be related
to the fact that cultured osteoblasts were not previously sub-
jected to cellular stress, such as nutritional restriction, which
has been reported by many workers as a predictive factor for
greater biostimulation [25, 27]. The cellular stress protocol
was not used in the present study because the osteoblasts had
already been subjected to the toxic effects of ZA, which
seemed to be sufficiently high to inhibit the biomodulation
of the cultured cells.
Regarding cell morphology, no alterations were observed
in cultured human osteoblasts subjected to LLLT at all select-
ed parameters, as previously demonstrated for other cell types
[16]. SEM evaluation, which is an important tool for the
morphologic evaluation of cells, can determine the cytotoxic
effects of several treatments [28, 29] such as observed for ZA
[18, 23]. Despite the fact that LLLT did not biostimulate the
cultured osteoblasts, cell morphology was maintained during
the study, thus determining the cells’ resistance threshold.
The positive effects of LLLT on areas of osteonecrosis
could be related to cellular biostimulation, as recently de-
scribed by our group (eu laser phys) However, so far, only
one study has been carried out to assess the effects of LLLTon
ZA-treated osteoblasts [30] The authors demonstrated that
LLLT applied to cultured human osteoblasts (SaOS-2) sub-
jected to ZA treatment for 24 and 48 h showed increased ALP
Table 5 Gene expression of Col-I by osteoblasts after ZA and LLLT treatment
ZA Energy doses (J/cm2)
0 0.5 1.5 3 5 7
+ 0.593
(0.547–0.636) B, b
1.918
(1.494–1.993) A, a
1.863
(1.648–2.015) A, a
1.958
(1.927–1.979) A, a
0.857
(0.682–1.043) A, ab
0.932
(0.832–1.039) B, ab
− 1.000
(0.983–1.016) A, ab
2.293
(1.559–3.044) A, a
1.952
(1.893–1.992) A, ab
2.039
(1.471–2.890) A, ab
0.809
(0.688–0.932) A, b
1.212
(1.156–1.293) A, ab
Values indicate median (25th to 75th percentiles), n=4
A, a Same upper-case letters in columns and lower-case letters in rows indicate no statistically significant difference (Mann–Whitney, p>0.05)
Table 6 Gene expression of ALP by osteoblasts after ZA and LLLT treatment
ZA Energy doses (J/cm2)
0 0.5 1.5 3 5 7
+ 0.344
(0.295–0.404) B, a
0.548
(0.442–0.624) B, a
0.334
(0.293–0.339) B, a
0.555
(0.521–0.605) B, a
0.486
(0.353–0.653) B, a
0.428
(0.347–0.488) B, a
− 1.045
(0.905–1.097) A, ab
1.975
(1.497–2.167) A, ab
2.167
(2.136–2.360) A, a
1.797
(1.382–2.188) A, ab
0.871
(0.830–0.910) A, b
1.211
(1.154–1.308) A, ab
Values indicate median (25th to 75th percentiles), n=4
A, a Same upper-case letters in columns and lower-case letters in rows indicate no statistically significant difference (Mann–Whitney, p>0.05)
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Fig. 1 Morphology of cultured human osteoblasts (Saos-2) subjected to
LLLTat different energy doses (aControl group. b 0.5 J/cm2. c 1.5 J/cm2.
d 3 J/cm2. e 5 J/cm2. f 7 J/cm2). No significant difference was observed
between LLLT-treated cells and the control group. All images show
adherent and confluent cells. SEM, original magnification ×200
Fig. 2 Morphology of cultured human osteoblasts (Saos-2) subjected to
ZA treatment and LLLTat different energy doses (a ZA. bZA+0.5 J/cm2.
c ZA+1.5 J/cm2. d ZA+3 J/cm2. e ZA+5 J/cm2. f ZA+7 J/cm2). For all
ZA-treated groups, a significant decrease in adherent cell numbers was
observed. For group E, where LLLTwas applied, an increase in adherent
cells can be observed, compared with the ZA-treated group (a). SEM,
original magnification ×200
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activity and numbers of viable osteoblasts [30] Despite the
similarity of methodology used by the authors compared with
that used in the present study, the data obtained in both
investigations cannot be compared, because the LLLT speci-
fications were not reported,[30] and because, as already men-
tioned, current studies have demonstrated that different laser
parameters cause various cell responses [15]. Therefore, in
addition to several available studies about the effects of LLLT
on different cell types, the lack of standardization of laser
irradiation protocols for in vitro and in vivo investigations
does not allow for adequate comparison among all data
obtained.
Considering previous results [18, 30] and based on analysis
of the data obtained in the present study, one may suggest that
LLLT at specific parameters can promote biostimulation of
cultured cells whether or not they are treated with ZA. How-
ever, further studies are needed to elucidate the effects of
LLLT on ZA-treated cells and to improve and standardize
the use of this kind of therapy as an adjuvant for the treatment
of osteonecrosis.
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